Rabenandrasana C, Baghdiguian S, Roccabianca M, Brunet M, Marvaldi J, Fantini J
CNRS URA 202, Université de Provence, Marseille, France.
Cancer Lett. 1990 Sep;53(2-3):109-15. doi: 10.1016/0304-3835(90)90202-9.
Suramin, a drug currently used for advanced malignancy, induces the differentiation of the human colonic adenocarcinoma cell clone HT29-D4 and this process is correlated with a decreased glycolytic activity. We investigated the effects of suramin on HT29-D4 cells in the presence of various glucose concentrations. The main result of this study is that suramin has only an effect on HT29-D4 cell growth and differentiation when the concentration of glucose is above 10 mM. Therefore the efficiency of suramin as an anticancer drug may be greater on poorly differentiated tumoral cells with a high proliferative capacity.
苏拉明是一种目前用于晚期恶性肿瘤的药物，它可诱导人结肠腺癌细胞克隆HT29-D4分化，且这一过程与糖酵解活性降低相关。我们研究了在不同葡萄糖浓度下苏拉明对HT29-D4细胞的影响。本研究的主要结果是，仅当葡萄糖浓度高于10 mM时，苏拉明才对HT29-D4细胞的生长和分化有影响。因此，苏拉明作为抗癌药物，对增殖能力高的低分化肿瘤细胞可能更有效。
